Logo

The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes

Share this

The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes

Shots:

  • EMDAC has voted 10-7- confirming that the benefits of teplizumab outweigh the risks supporting the approval to delay T1D Mellitus
  • The recommendation is based on a pivotal TN-10 study in which a single 14-day course of teplizumab delayed insulin-dependent- clinical-stage disease by a median of at least 2yrs. in pre symptomatic patients with stage 2 T1D compared to PBO
  • The US FDA has granted BTD and PR to teplizumab’s BLA. The anticipated PDUFA date is July 2- 2021

  Ref: PRNewswire | Image: PRNewswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions